FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is great news. I was worried that they would remove the approval based on the study mentioned. The study showed "no significant increase in overall survival". That study did not take into account how Avastin is used in the real world. In the real world it is used in combination with many other things and is a very useful drug. Our virtual trial is tracking the combinations. One that looks exceptionally good (although only 4 patients used the combination) is Avastin plus Optune. 2 of the 4 patients died, but they survived an average of 30 months. The other 2 are alive - one for 22 months so far and the other an amazing over 8 years.
Posted on: 12/06/2017
Click HERE to return to brain tumor news headlines